公开(公告)号：EP2604279A1

公开(公告)日：2013-06-19

申请号：EP13159549.8

申请日：2009-03-27

申请人： ZymoGenetics, Inc.

发明人： Sivakumar, Pallavur V. ,  Gilbertson, Debra G. ,  Snavely, Marshall D. ,  Mabry, George R. ,  Yi, Eugene C. ,  Yao, Yue ,  Presnell, Scott R.

IPC分类号： A61K39/395 ,  A61P35/00 ,  C07K16/22 ,  C07K16/28

CPC分类号： C07K16/00 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/90 ,  C07K2317/92

摘要： There is provided an isolated antibody that binds to VEGF-A and neutralizes VEGF-A activity, said antibody comprising a V L domain comprising CDRs LCDR1, LCDR2 and LCDR3, and a V H domain comprising CDRs HCDR1, HCDR2 and HCDR3, wherein:
LCDR1 has the amino acid sequence shown in SEQ ID NO: 448;
LCDR2 has the amino acid sequence shown in SEQ ID NO: 449;
LCDR3 has the amino acid sequence shown in SEQ ID NO: 450;
HCDR1 has the amino acid sequence shown in SEQ ID NO: 451;
HCDR2 has the amino acid sequence shown in SEQ ID NO: 452;
HCDR3 has an amino acid sequence selected from the group consisting of SEQ ID NOs: 453-461.

摘要翻译： 提供了结合VEGF-A并中和VEGF-A活性的分离的抗体，所述抗体包含包含CDR1 LCDR1，LCDR2和LCDR3的VL结构域，以及包含CDR HCDR1，HCDR2和HCDR3的VH结构域，其中：LCDR1具有 SEQ ID NO：448所示的氨基酸序列; LCDR2具有SEQ ID NO：449所示的氨基酸序列; LCDR3具有SEQ ID NO：450所示的氨基酸序列; HCDR1具有SEQ ID NO：451所示的氨基酸序列; HCDR2具有SEQ ID NO：452所示的氨基酸序列; HCDR3具有选自SEQ ID NO：453-461的氨基酸序列。

公开(公告)号：EP2604280A3

公开(公告)日：2013-10-16

申请号：EP13159556.3

申请日：2009-03-27

申请人： ZymoGenetics, Inc.

发明人： Sivakumar, Pallavur V. ,  Gilbertson, Debra G. ,  Snavely, Marshall D. ,  Mabry, George R. ,  Yi, Eugene C. ,  Yao, Yue ,  Presnell, Scott R.

IPC分类号： A61K39/395 ,  A61P35/00 ,  C07K16/22 ,  C07K16/28

CPC分类号： C07K16/00 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/90 ,  C07K2317/92

摘要： There is provided an isolated antibody that binds to the extracellular domain of PDGFRβ and neutralizes PDGFRβ activity, said antibody comprising a V L domain comprising CDRs LCDR1, LCDR2, and LCDR3 and a V H domain comprising CDRs HCDR1, HCDR2, and HCDR3, wherein:
LCDR1 has the amino acid sequence shown in SEQ ID NO: 433, optionally the amino acid sequence shown in SEQ ID NO: 443;
LCDR2 has the amino acid sequence shown in SEQ ID NO: 434;
LCDR3 has the amino acid sequence shown in SEQ ID NO: 435, optionally the amino acid sequence shown in SEQ ID NO: 444;
HCDR1 has the amino acid sequence shown in SEQ ID NO: 436, optionally the amino acid sequence shown in SEQ ID NO: 445;
HCDR2 has the amino acid sequence shown in SEQ ID NO: 437;
HCDR3 has an amino acid sequence selected from the group consisting of SEQ ID NOs: 438-442

摘要翻译： 提供了结合PDGFR2的细胞外结构域并中和PDGFR2活性的分离的抗体，所述抗体包含包含CDR1 LCDR1，LCDR2和LCDR3的VL结构域和包含CDR HCDR1，HCDR2和HCDR3的VH结构域，其中：LCDR1具有 SEQ ID NO：433所示的氨基酸序列，任选地SEQ ID NO：443所示的氨基酸序列; LCDR2具有SEQ ID NO：434所示的氨基酸序列; LCDR3具有SEQ ID NO：435所示的氨基酸序列，任选地SEQ ID NO：444所示的氨基酸序列; HCDR1具有SEQ ID NO：436所示的氨基酸序列，任选地是SEQ ID NO：445所示的氨基酸序列; HCDR2具有SEQ ID NO：437所示的氨基酸序列; HCDR3具有选自SEQ ID NO：438-442的氨基酸序列

公开(公告)号：EP2604280A2

公开(公告)日：2013-06-19

申请号：EP13159556.3

申请日：2009-03-27

申请人： ZymoGenetics, Inc.

发明人： Sivakumar, Pallavur V. ,  Gilbertson, Debra G. ,  Snavely, Marshall D. ,  Mabry, George R. ,  Yi, Eugene C. ,  Yao, Yue ,  Presnell, Scott R.

IPC分类号： A61K39/395 ,  A61P35/00 ,  C07K16/22 ,  C07K16/28

CPC分类号： C07K16/00 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/90 ,  C07K2317/92

摘要： There is provided an isolated antibody that binds to the extracellular domain of PDGFRβ and neutralizes PDGFRβ activity, said antibody comprising a V L domain comprising CDRs LCDR1, LCDR2, and LCDR3 and a V H domain comprising CDRs HCDR1, HCDR2, and HCDR3, wherein:
LCDR1 has the amino acid sequence shown in SEQ ID NO: 433, optionally the amino acid sequence shown in SEQ ID NO: 443;
LCDR2 has the amino acid sequence shown in SEQ ID NO: 434;
LCDR3 has the amino acid sequence shown in SEQ ID NO: 435, optionally the amino acid sequence shown in SEQ ID NO: 444;
HCDR1 has the amino acid sequence shown in SEQ ID NO: 436, optionally the amino acid sequence shown in SEQ ID NO: 445;
HCDR2 has the amino acid sequence shown in SEQ ID NO: 437;
HCDR3 has an amino acid sequence selected from the group consisting of SEQ ID NOs: 438-442

摘要翻译： 提供了与PDGFRβ的胞外结构域结合并中和PDGFRβ活性的分离的抗体，所述抗体包含含有CDR LCDR1，LCDR2和LCDR3的VL结构域和包含CDR HCDR1，HCDR2和HCDR3的VH结构域，其中：LCDR1具有 SEQ ID NO：433所示的氨基酸序列，任选的SEQ ID NO：443所示的氨基酸序列; LCDR2具有SEQ ID NO：434所示的氨基酸序列; LCDR3具有SEQ ID NO：435所示的氨基酸序列，任选地SEQ ID NO：444所示的氨基酸序列; HCDR1具有SEQ ID NO：436中所示的氨基酸序列，任选地SEQ ID NO：445中所示的氨基酸序列; HCDR2具有SEQ ID NO：437所示的氨基酸序列; HCDR3具有选自SEQ ID NO：438-442的氨基酸序列